ClinicalTrials.gg
Drug

Brentuximab Vedotin clinical trials

Also written Adcetris, SGN-35 and cAC10-vcMMAE.

studies test it
154
open now
24
in phase 3
17
first study started
2006

How each study uses Brentuximab Vedotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Brentuximab Vedotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
19 Aug 2011 · ADCETRIS · BLA 125388 (FDA, Drugs@FDA)
European Union
25 Oct 2012 · Adcetris · EMEA/H/C/002455 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Brentuximab Vedotin
142
Anti-CD30 Antibody-Drug Conjugate SGN-35
33
ADC SGN-35
28
Anti-CD30 Monoclonal Antibody-MMAE SGN-35
28
Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35
28

Brand

Adcetris
82

Development codes

SGN-35
74
cAC10-vcMMAE
28

Studies by the year they started

153 studies that test it; most in 2013 (24); 1 more planned to start later

Studies that test Brentuximab Vedotin, by start year
YearStudies
20061
20081
20094
20103
20117
201210
201324
201412
201514
201612
201710
201813
20198
20206
20214
202210
20235
20245
20253
20261

Who runs them

Industry 37 · Other 117

Seagen Inc. (21) · City of Hope Medical Center (9) · National Cancer Institute (NCI) (8) · Takeda (7) · M.D. Anderson Cancer Center (7) · Memorial Sloan Kettering Cancer Center (5) · Massachusetts General Hospital (5) · Fondazione Italiana Linfomi - ETS (5)

Often tested with

Tested in the same studies.

Nivolumab (16) · Dacarbazine (16) · Doxorubicin (15) · Vinblastine (11) · Pembrolizumab (11) · Etoposide (9) · Cyclophosphamide (8) · Rituximab (6)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 11

Studies that test Brentuximab Vedotin.

Studies

Open first, then newest update. How each study uses Brentuximab Vedotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 154

See all 154 studies that test Brentuximab Vedotin →

Given beside what is tested · 15 — Brentuximab Vedotin is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with Brentuximab Vedotin

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call Brentuximab Vedotin · ClinicalTrials.gg INT006839

  • MeSH (NLM) D000079963Brentuximab VedotinConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 7XL5ISS668BRENTUXIMAB VEDOTINConfirmed FDA, NLM, Wikidata
  • RxNorm 1147320Confirmed FDA, Wikidata
  • Wikidata Q422324brentuximab vedotinConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C66944Brentuximab VedotinOne source FDA
  • DrugBank DB08870One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.